Breast Cancer

The PREFERABLE-EFFECT study found that supervised resistance and aerobic exercise were associated with reduced fatigue in patients with metastatic breast cancer.

Data from the DESTINY-Breast06 trial support the FDA breakthrough therapy designation for T-DXd in HR–positive, HER2-low, or HER2-ultralow breast cancer.

Phase 1 AC699-001 results evaluating the safety and efficacy of AC699 in patients with breast cancer subtypes support the Fast Track designation.

Findings from a population-based study suggest patients with POI may need genetic counseling regarding future risk of reproductive cancers.

Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma.

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Retrospective analysis found that cryoablation was associated with infrequent AEs and low recurrence rates among patients with breast cancer.

A holistic integration of time series and static data present in the learning approach can lead to improved understanding of breast cancer outcomes.

In terms of cancer detected per 1000 MRI exams, the AI scoring method was close to 4 times more efficient vs traditional breast density measures.

SP-1-303’s ATM-activating and HDAC-inhibiting properties may overcome limitations seen in prior attempts to combine therapeutic agents and HDAC inhibitors.